Form 4: Longboard Pharmaceuticals CMO Exercises Stock Options, Acquires Shares
SEC Form 4 Filing
Longboard Pharmaceuticals' Chief Medical Officer, Randall Kaye, exercised stock options to acquire 30,554 shares of common stock.
Summary
- Randall Kaye, the Chief Medical Officer of Longboard Pharmaceuticals, exercised stock options to purchase 30,554 shares of common stock at a price of $6 per share.
- This transaction increased Kaye's direct holdings to 48,474 shares of common stock.
- The exercised options were part of a larger grant, with the remaining options vesting over time.
- Kaye also holds 175,946 stock options and 17,920 restricted stock units (RSUs) that will vest in the future.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction, which is generally positive as it shows executive confidence. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The exercise of stock options by a key executive like the CMO can be seen as a positive sign of confidence in the company's future prospects.
- The acquisition of shares increases the executive's alignment with shareholder interests.
Industry Context
This is a routine filing related to executive compensation and is common in the pharmaceutical industry where stock options are a significant part of executive pay packages.
Comparison to Industry Standards
- Stock option exercises are a common practice in the biotech and pharmaceutical industries, often used to incentivize and align management with shareholder interests.
- The vesting schedule of the options and RSUs is typical for executive compensation packages in similar companies.
- Companies like Amgen, Gilead Sciences, and Biogen also use stock options and RSUs as part of their executive compensation plans.
Stakeholder Impact
- The transaction increases the alignment of the CMO's interests with those of shareholders.
- The exercise of options does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/08/2024 | Date of grant of 17,920 restricted stock units (RSUs). |
| 02/09/2024 | Date of Form 4 filing reporting the grant of 17,920 restricted stock units (RSUs). |
| 03/21/2023 | Date when 1/4th of the shares subject to the stock option vested. |
| 11/19/2024 | Date of the stock option exercise and share acquisition. |
| 02/08/2025 | First vesting date for the restricted stock units (RSUs). |
| 03/20/2032 | Expiration date of the stock options. |
Keywords
stock options, insider trading, share acquisition, Longboard Pharmaceuticals, Randall Kaye, CMO, equity, LBPH
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.